ImmuCell Corporation
ICCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $56,538 | $62,858 | $43,017 | $46,015 |
| - Cash | $3,886,198 | $5,998 | $4,599 | $3,758 |
| + Debt | $5,706,958 | $14,265 | $14,659 | $15,100 |
| Enterprise Value | $1,877,298 | $71,124 | $53,077 | $57,357 |
| Revenue | $5,506 | $6,445 | $8,067 | $7,751 |
| % Growth | -14.6% | -20.1% | 4.1% | – |
| Gross Profit | $2,363 | $2,818 | $3,354 | $2,832 |
| % Margin | 42.9% | 43.7% | 41.6% | 36.5% |
| EBITDA | $544 | $1,297 | $2,242 | $1,320 |
| % Margin | 9.9% | 20.1% | 27.8% | 17% |
| Net Income | -$140 | $502 | $1,447 | $515 |
| % Margin | -2.5% | 7.8% | 17.9% | 6.6% |
| EPS Diluted | -0.02 | 0.056 | 0.16 | 0.058 |
| % Growth | -136% | -65.3% | 177.8% | – |
| Operating Cash Flow | – | $1,601 | $1,574 | -$3 |
| Capital Expenditures | – | -$155 | -$329 | -$196 |
| Free Cash Flow | – | $1,446 | $1,245 | -$199 |